Aspirin: How a Century-Old Pill is Changing Cancer Policy

Evidence is mounting that aspirin, one of the world’s oldest and most widely used painkillers, plays a critical role in preventing certain cancers and stopping their spread (metastasis). Recent breakthroughs from the UK and Sweden have already begun reshaping national health policies as of April 2026. Originally derived from willow bark in Mesopotamia 4,400 years ago, this inexpensive drug is moving from the medicine cabinet to the front lines of oncology.

Lynch Syndrome: A 50% Reduction in Risk

The most profound evidence of aspirin’s preventative power comes from research on Lynch Syndrome, a genetic condition that significantly increases the risk of colorectal and other cancers.

• The Study: Led by Professor Sir John Burn at Newcastle University, the landmark CaPP3 study followed high-risk patients for over a decade.

• The Result: Patients who took a regular low dose (75–100 mg) of aspirin for at least two years saw their risk of developing colon cancer drop by 50%.

• Policy Change: Following these results, the UK updated its primary care guidelines in April 2026, officially recommending that individuals with Lynch Syndrome begin a regular aspirin regimen as early as their 20s or 30s.

Stopping the Spread (Metastasis)

Aspirin is proving to be more than just a preventative measure; it is also a powerful tool in post-surgical care to prevent cancer from returning.

The Swedish Breakthrough (ALASCCA Study):

In September 2025, Professor Anna Martling of the Karolinska Institute published a revolutionary study involving nearly 3,000 colorectal cancer patients. The research found that for patients with specific PI3K pathway mutations, taking 160 mg of aspirin daily after surgery reduced the risk of recurrence by half.

As a direct result, Sweden implemented a new policy in January 2026 to screen all bowel cancer patients for these mutations and offer low-dose aspirin as a precision therapy.

The Science: How Does Aspirin Stop Cancer?

For years, the mechanism was a mystery. Today, scientists point to two primary biological “brakes” that aspirin applies to cancer:

1. Enzyme Suppression (COX-2): Aspirin inhibits the COX-2 enzyme, which often signals uncontrolled cell growth and inflammation in tumors.

2. Immune System “Unmasking”: New research from Professor Rahul Roychoudhuri at Cambridge University (published in Nature) discovered that tumors use a clotting factor called Thromboxane A2 to hide from the immune system. Aspirin blocks this factor, essentially “stripping away the invisibility cloak” from cancer cells and allowing the body’s T-cells to find and destroy them.

A Word of Caution: Not for Everyone

Despite these optimistic findings, medical experts issued a critical warning: Do not start a daily aspirin regimen without consulting a doctor.

Professor Martling emphasizes that while aspirin is a powerful precision medicine for high-risk groups or specific cancer patients, it can be dangerous for a healthy general population. Ongoing trials involving 11,000 participants are currently testing aspirin’s effects on breast, prostate, and stomach cancers to determine if it will become a standard part of global cancer therapy by the late 2020s.

source: BBC